ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and a TLR9 agonist. It induces the production of NO and iNOS and enhances apoptosis. ODN 1826 sodium boosts immune surveillance and increases the size of atherosclerotic plaques. It exhibits antitumor activity against lung cancer, glioma, and melanoma.
Target-Kategorie:
TLR|||NO Synthase|||Apoptosis
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
